Apr 24, 2025
Price of Key DR-TB Medicine Drops 25% as TB Alliance's Multi-Manufacturer Strategy Expands Access
Nov 10, 2024
TB Alliance Joins Indonesia's High-Level Meeting on TB
Mar 24, 2024
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Mar 24, 2024
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
Feb 12, 2020
TB Alliance Names Dr. Daniel Everitt Vice President and Chief Medical Officer
Feb 03, 2020
Jane Griffiths Joins TB Alliance Board of Directors
Aug 14, 2019
FDA Approves Breakthrough Drug to Treat Extensively Drug-Resistant Tuberculosis
Aug 14, 2019
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
Aug 14, 2019
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Jun 12, 2019
Mitchell Warren Elected President of TB Alliance Stakeholders Association, Joins Board of Directors
Jun 06, 2019
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
Apr 18, 2019
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)
Mar 27, 2019
GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis
Jan 15, 2019
Jan Lundberg Joins TB Alliance Board of Directors
Dec 12, 2018
GHIT Fund Announces New Investments in Vaccines for Dengue and Leishmaniasis, and Drug Screening for Malaria and Tuberculosis
Aug 24, 2018
Global Tuberculosis (TB) Drugs/Therapeutics Market, 2018-2025 - Key Players are J&J Services, Lupin, Pfizer, Novartis, Macleods Pharmaceuticals, and Otsuka Pharmaceutical
Jul 18, 2018
TB Drugs Market Size Worth $1.38 Billion by 2025 | CAGR: 5.2%: Grand View Research, Inc.
Jul 13, 2018
TB Alliance Names Angela Vanderploeg as Chief Financial Officer
Jul 04, 2018
The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025
Mar 28, 2018
As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (US$123 Million)